TapImmune Культура компании

Dr. Glynn Wilson, Ph.D., has been the Chairman at TapImmune, Inc. since June 2009 and has been its Strategic Advisor since September 22, 2017. Dr. Wilson serves as the President and Chief Executive Officer of Auriga Pharmaceuticals, a Specialty Pharmaceutical Company. Dr. Wilson serves as the President of GW Group. Dr. Wilson served as the President of TapImmune, Inc. from November 2015 to July 18, 2016 and again from April 27, 2017 to September 22, 2017 and served as its Chief Executive Officer from November 2015 to September 22, 2017 and Acting Principal Accounting Officer. He served as the President of Auriga Laboratories, Inc. until May 17, 2006 and also served as its Chief Scientific Officer until August 25, 2006. He served as the Head for Drug Delivery of SmithKline Beecham Pharmaceuticals and Executive Vice President for Research & Development of Tacora Corporation, he was responsible for conceiving and developing lead products (currently in Phase II clinical development), and providing leadership in the merging of Tacora Corporation with Access Pharmaceuticals. Dr. Wilson served as the Worldwide Head of Drug Delivery of SmithKline Beecham from 1989 to 1994 and the Chief Scientific Officer of Tacora Corporation from 1994 to 1997. Dr. Wilson served as the Vice President of Research & Development at Access Pharmaceuticals from 1997 to 1998 and the President and Chief Executive Officer of PharmaSpec Corporation from 1999 to 2000. In addition, he was a Founding Member of the Advanced Drug Delivery Group at Ciba-Geigy. He has been an Adjunct Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah since 1994. He serves as the Chairman of Medical and Clinical Board of Posh Cosmeceuticals Inc. Dr. Wilson served as the Chairman and Director of Auriga Laboratories, Inc. until May 17, 2006. He has been a Director of Genemax Corp. since February 2005 and TapImmune, Inc. since February 2005. He was a Faculty Member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Stanford Moore and William Stein from 1974 to 1979. Dr. Wilson obtained his Ph.D. in Biochemistry at Heriot-Watt University, Edinburgh in 1972.

Mr. Michael J. Loiacono has been the Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer at TapImmune, Inc. since August 25, 2016. Mr. Loiacono served as an Interim Chief Financial Officer and Interim Chief Accounting Officer at Global Axcess Corp. since May 14, 2013. He served as the Chief Financial Officer of Global Axcess Corp. from June 1, 2006 to April 23, 2013 and also served as its Controller from March 2006 to April 23, 2013 and Consultant since April 23, 2013. He served as the Chief Accounting Officer of Global Axcess Corp. Prior to joining Global Axcess Corp., he served as Vice President for Finance of InfiniRoute Networks Inc., from August 2005 to March 2006 which was acquired by TNS, Inc. Before his role at InfiniRoute, he served as Vice President for Finance of Reach Services, USA from November 2004 to August 2005 and Controller and Director of Finance from July 1998 to October 2004 for ITXC Corp., which was acquired by Teleglobe, Inc. He has also held financial management positions at Voxware, Inc. from March 1996 to July 1998 and Dendrite International, Inc. from August 1994 to March 1996, two publicly traded companies. He has InfiniRoute an established background with 17 years of financial management and analysis experience in telecommunications and software industries. Mr. Loiacono holds a Bachelor of Science Degree from Rutgers University, which he received in June 1988.

Ms. Elizabeth Donnelly has been a Director of Administration at TapImmune, Inc. since September 21, 2016. Over the 20 years, Ms. Donnelly has worked in Human Resources for a large logistics company, a Data Analyst for a large MRO company. She worked for System Designs, Inc. (SDI) as the Office Manager for 8 years.

Dr. Richard Tilton Kenney, M.D., F.A.C.P., has been Acting Chief Medical Officer at TapImmune, Inc. since December 06, 2017 and served as its Medical Director since May 1, 2017. Dr. Kenney has been Head of Clinical Development at TapImmune, Inc. since May 2017. Dr. Kenney served as Consultant Medical Director at TapImmune, Inc. since May 05, 2017 and its Scientific Adviser since March 2017. Dr. Kenney has broad background in designing and implementing clinical trials in immunotherapy and infectious disease. He presently serves as president of ClinReg Biologics LLC. Prior to this role, he served as Principal Medical Advisor and Chief Medical Officer of Immune Design Corp, where he established and led the clinical development, pharmacovigilance and regulatory affairs groups to advance the development and commercialisation of the company's cancer prime-boost immunotherapeutic and vaccines. Earlier, Dr Kenney served as Chief Medical Officer of Crucell Holland BV, where he directed clinical development of a broad platform of vaccines. He also served as senior vice president, Clinical Development for Vical Incorporated, where he led the clinical development of DNA vaccines for cancer immunotherapy and infectious diseases. Dr Kenney held key positions in vaccine development at GSK Biologicals from 2005 to 2009, served as Senior Director of Global Clinical R&D, Vaccines for Viral Diseases. Dr. Kenney earned his MD degree at Harvard Medical School, completed his residency in Internal Medicine at Duke University Medical Center, and a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases.